Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 12
Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice
Matthew D. Sims, MD, PhD, FACP, FIDSA, discusses how fecal microbiota transplantation therapies are administered and shares his clinical experience.
Video Player is loading.
Video content above is prompted by the following:
- How are these FMT therapies administered?
- What has your experience been with administering each of these therapies?
- What have you heard from your patients?
Recent Videos
Education and Advocacy in DC: The PLF C Diff Summit and Lobby Day
Targeting C difficile with Oxygen-Based Therapy
Targeting the C Diff Pathogen and Its Immune-Suppressing Toxins
mRNA Vaccine Shows Potential for C difficile Infections
Two Years After its FDA Approval, Rebyota Continues to Show Efficacy and Safety
Due to FDA Policy Change, Fecal Microbiota Transplants Are in a Tenuous Position
Targeted Prophylaxis Reduces Hospital-Onset C difficile Infections in High-Risk Patients
Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections
Physicians’ Use of Fecal Microbiota Transplant for Recurrent C. difficile Infections
Getting Patients Involved in C diff Advocacy, Treatment Guidelines
Related Content
